Medicare AdvantageDocumentationMedium impact
MA08.082p, Efbemalenograstim alfa-vuxw (Ryzneuta®), Eflapegrastim-xnst (Rolvedon™), Pegfilgrastim (Neulasta®) and Related Biosimilars
Independence Blue Cross·Oncology, Hematology, Pharmacy·Pharmacy
Effective date
Apr 20, 2026
We identified it
Jun 19, 2026
Summary
This policy update addresses medical necessity criteria, medical coding, and general guidelines for G-CSF (granulocyte-colony stimulating factor) products including Ryzneuta®, Rolvedon™, Neulasta®, and related biosimilars. The policy became effective April 20, 2026, and the billing team must review updated coverage criteria and coding requirements to ensure compliant claim submissions.
Action Required
By April 20, 2026: Billing and clinical teams must review the full policy text at the provided URL to identify specific medical necessity criteria, approved indications, and any coding changes for G-CSF products (Ryzneuta®, Rolvedon™, Neulasta®, and biosimilars). Update billing system rules, prior authorization protocols, and provider documentation templates to reflect new requirements. Verify which specific HCPCS codes apply under updated guidelines. Communicate changes to providers and front-desk staff. Claims submitted without compliance to updated medical necessity criteria may be denied.